 | Thinking about buying stock in Super League Gaming, Soligenix, Vascular Biogenics, BioLineRx, or electroCore?
prnewswire.com - March 4 at 1:13 PM |
 | Vascular Biogenics (NASDAQ:VBLT) Shares Gap Up to $1.84
americanbankingnews.com - March 4 at 12:32 PM |
 | VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
finance.yahoo.com - March 4 at 8:12 AM |
| Comparing Vascular Biogenics (NASDAQ:VBLT) and Crinetics Pharmaceuticals (NASDAQ:CRNX)
americanbankingnews.com - March 3 at 10:16 PM |
| Vascular Biogenics (NASDAQ:VBLT) Trading 6.5% Higher
americanbankingnews.com - March 2 at 7:02 PM |
| VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme
finance.yahoo.com - March 1 at 8:29 AM |
 | 65 Stocks Moving In Tuesday's Mid-Day Session
feeds.benzinga.com - February 23 at 12:24 PM |
| Vascular Biogenics (NASDAQ:VBLT) Shares Gap Up to $2.23
americanbankingnews.com - February 23 at 10:46 AM |
 | 48 Stocks Moving in Tuesday's Pre-Market Session
msn.com - February 23 at 8:06 AM |
| Vascular Biogenics (NASDAQ:VBLT) Trading Down 12.5%
americanbankingnews.com - February 22 at 10:20 PM |
|
| Vascular Biogenics' Ovarian Cancer Gene Therapy Study To Continue, Recommends An Independent Committee
finance.yahoo.com - February 22 at 8:04 PM |
| VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
finance.yahoo.com - February 22 at 8:36 AM |
| Vascular Biogenics (NASDAQ:VBLT) Trading 12.6% Higher
americanbankingnews.com - February 10 at 7:16 PM |
| Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation
finance.yahoo.com - January 19 at 3:33 PM |
| VBL Therapeutics Announces First Patient in Europe in the OVAL Trial
finance.yahoo.com - December 29 at 8:23 AM |
| VBL Therapeutics Announces Insider Buying
finance.yahoo.com - December 7 at 7:52 AM |
| Vascular Biogenics Ltd. (NASDAQ:VBLT) Analysts Just Slashed Next Year's Revenue Estimates By 16%
finance.yahoo.com - November 18 at 9:07 AM |
| Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 16 at 1:01 PM |
| How Much Is Vascular Biogenics Ltd. (NASDAQ:VBLT) Paying Its CEO?
finance.yahoo.com - November 16 at 1:01 PM |
| Vascular Biogenics: Q3 Earnings Insights
benzinga.com - November 16 at 8:00 AM |
| Earnings Outlook For Vascular Biogenics
benzinga.com - November 13 at 12:32 PM |
| VBL Therapeutics to Present at the H.C. Wainwright 6th Annual Israel Conference
finance.yahoo.com - November 5 at 7:36 AM |
| VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16
finance.yahoo.com - November 2 at 7:07 AM |
| VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of Cancer
finance.yahoo.com - October 23 at 8:42 PM |
| VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
finance.yahoo.com - September 21 at 7:23 PM |
| Who Has Been Buying Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares?
finance.yahoo.com - September 17 at 6:11 PM |
| VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conference
finance.yahoo.com - September 15 at 8:38 AM |
 | Thinking about buying stock in Avinger, Vascular Biogenics, Intra-Cellular Therapies, Agenus, or Co-Diagnostics?
marketwatch.com - September 13 at 8:25 PM |
| VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting
finance.yahoo.com - September 11 at 12:27 PM |
| VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer
finance.yahoo.com - September 10 at 10:16 AM |
|
| VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
finance.yahoo.com - September 8 at 9:16 AM |
 | Vascular Biogenics Ltd (VBLT) CEO Dror Harats on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 1:41 PM |
| Vascular Biogenics: Q2 Earnings Insights
benzinga.com - August 13 at 8:40 AM |
| VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - August 13 at 8:40 AM |
| VBL Therapeutics late-stage study of lead drug in ovarian cancer to continue
seekingalpha.com - August 12 at 12:36 PM |
| VBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer
finance.yahoo.com - August 12 at 12:36 PM |
| Earnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to Decline
finance.yahoo.com - August 6 at 6:07 PM |
| VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13
finance.yahoo.com - August 3 at 8:29 AM |
| Growth Investors: Industry Analysts Just Upgraded Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Revenue Forecasts By 24%
finance.yahoo.com - June 25 at 10:12 AM |
| VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
finance.yahoo.com - June 22 at 10:13 AM |
| VBL Presents New Data on the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Rheumatoid Arthritis at the EULAR 2020 Congress
finance.yahoo.com - June 4 at 11:03 AM |
 | BRIEF-VBL Presents Positive Interim Data From Pivotal Study In Ovarian Cancer
www.reuters.com - June 1 at 10:39 PM |
| VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer at the ASCO20 Annual Meeting, Showing 58% or Higher Objective Response Rate
finance.yahoo.com - June 1 at 7:37 AM |
| Earnings Update: Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Are Boosting Their Estimates
finance.yahoo.com - May 18 at 2:10 PM |
| VBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
finance.yahoo.com - May 18 at 9:09 AM |
| This Just In: Analysts Are Boosting Their Vascular Biogenics Ltd. (NASDAQ:VBLT) Outlook for This Year
finance.yahoo.com - May 15 at 3:42 PM |
| Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 5:45 PM |
| Vascular Biogenics (VBLT) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 14 at 12:45 PM |
| Recap: Vascular Biogenics Q1 Earnings
finance.yahoo.com - May 14 at 12:45 PM |
| VBL Therapeutics Announces First Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - May 14 at 7:43 AM |
